Taher Rayan, Bhanushali Palak, Allan Stephanie, Alvarez-Jimenez Mario, Bolton Heather, Dennison Laura, Wallace Brian E, Hadjistavropoulos Heather D, Hall Charlotte L, Hardy Amy, Henry Alasdair L, Lane Sam, Maguire Tess, Moreton Adam, Moukhtarian Talar R, Vallejos Elvira Perez, Shergill Sukhi, Stahl Daniel, Thew Graham R, Timulak Ladislav, van den Berg David, Viganò Noemi, Stock Ben Wensley, Young Katherine S, Yiend Jenny
Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.
Institute of Health and Wellbeing, University of Glasgow, UK.
BJPsych Open. 2024 Jun 3;10(4):e126. doi: 10.1192/bjo.2024.713.
Digital Mental Health Interventions (DMHIs) that meet the definition of a medical device are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. The MHRA uses procedures that were originally developed for pharmaceuticals to assess the safety of DMHIs. There is recognition that this may not be ideal, as is evident by an ongoing consultation for reform led by the MHRA and the National Institute for Health and Care Excellence.
The aim of this study was to generate an experts' consensus on how the medical regulatory method used for assessing safety could best be adapted for DMHIs.
An online Delphi study containing three rounds was conducted with an international panel of 20 experts with experience/knowledge in the field of UK digital mental health.
Sixty-four items were generated, of which 41 achieved consensus (64%). Consensus emerged around ten recommendations, falling into five main themes: Enhancing the quality of adverse events data in DMHIs; Re-defining serious adverse events for DMHIs; Reassessing short-term symptom deterioration in psychological interventions as a therapeutic risk; Maximising the benefit of the Yellow Card Scheme; and Developing a harmonised approach for assessing the safety of psychological interventions in general.
The implementation of the recommendations provided by this consensus could improve the assessment of safety of DMHIs, making them more effective in detecting and mitigating risk.
符合医疗器械定义的数字心理健康干预措施(DMHIs)在英国由药品和医疗产品监管局(MHRA)监管。MHRA采用最初为药品开发的程序来评估DMHIs的安全性。人们认识到这可能并不理想,MHRA和国家卫生与临床优化研究所正在进行的改革磋商就表明了这一点。
本研究的目的是就如何最好地调整用于评估安全性的医疗监管方法以适用于DMHIs达成专家共识。
对一个由20名在英国数字心理健康领域有经验/知识的专家组成的国际小组进行了一项包含三轮的在线德尔菲研究。
共提出64项内容,其中41项达成共识(64%)。围绕十项建议达成了共识,这些建议分为五个主要主题:提高DMHIs中不良事件数据的质量;重新定义DMHIs的严重不良事件;将心理干预中的短期症状恶化重新评估为一种治疗风险;最大化黄卡计划的益处;以及总体上制定一种统一的方法来评估心理干预的安全性。
实施这一共识提出的建议可以改进对DMHIs安全性的评估,使其在检测和减轻风险方面更有效。